Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) is a clinical-stage biopharmaceutical company committed to discovering and developing innovative and proprietary new therapeutics. Our current focus is on neuropsychiatric disorders and biodefense technologies. Our mission is to improve the lives of patients by identifying, researching and developing promising therapies which have the potential to address needs not currently fulfilled by existing products.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
TNX-102 Sublingual Tablet
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):